Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Meta-Anal. Jun 18, 2026; 14(2): 119849
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.119849
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.119849
Glucagon-like peptide-1-based incretin agonists in obesity-related heart failure with preserved ejection fraction: A systematic review and meta-analysis
Ehab Al Mashtoub, Anthony Bedran, Janette Al Banna, Charbel El Hachem, Nazih Obeid, Mostafa Msheik, Mohamad Tlais, Razan Abdulaal, Cardiology, University of Balamand, Beirut 1100, Beyrouth, Lebanon
Ali Hteit, Department of Cardiology, Georgian American University, Tbilisi 1100, Georgia
Author contributions: Al Mashtoub E and Tlais M conceived and designed the review; Bedran A and Hteit A independently screened titles and abstracts, performed full-text eligibility assessment, and extracted data; Msheik M adjudicated discrepancies; Abdulaal R and Al Banna J performed risk of bias assessment; El Hachem C and Obeid N conducted the statistical analyses and generated the meta-analytic figures; Mashtoub EA drafted the manuscript. All authors critically revised the manuscript for important intellectual content and approved the final version for submission.
Conflict-of-interest statement: All authors declare no conflict of interest related to this work. No funding was received for the design, conduct, or reporting of this systematic review and meta-analysis.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Mohamad Tlais, MD, Cardiology, University of Balamand, Hazmieh, Beirut 1100, Beyrouth, Lebanon. mmtlaiss22@gmail.com
Received: February 7, 2026
Revised: March 8, 2026
Accepted: March 19, 2026
Published online: June 18, 2026
Processing time: 125 Days and 8.7 Hours
Revised: March 8, 2026
Accepted: March 19, 2026
Published online: June 18, 2026
Processing time: 125 Days and 8.7 Hours
Core Tip
Core Tip: Glucagon-like peptide-1 (GLP)-1-based incretin agonists, including semaglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, produce consistent and clinically meaningful improvements in symptoms, functional capacity, and body weight in patients with obesity-related heart failure with preserved ejection fraction. Tirzepatide additionally reduced the composite of cardiovascular death or worsening heart failure events, establishing weight-centric pharmacotherapy as a promising disease-modifying strategy for this high-risk and previously treatment-resistant phenotype.